Clinical Trial Update: Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating docetaxel or abiraterone acetate with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer; study terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-sensitive Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Androgen deprivation therapy (Androgen deprivation therapy)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: University of Utah | Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2020-06-25